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Abstract
Introduction High-risk surgical patients are at increased risk of
fungal infections and candidaemia. Evidence from observational
and small randomised controlled studies suggests that
prophylactic fluconazole may be effective in reducing fungal
infection and mortality. We evaluated the effects of prophylactic
fluconazole on the incidence of candidaemia and hospital
mortality in immunocompetent high-risk surgical patients.
Methods Randomised controlled studies involving the use of
fluconazole in immunocompetent high-risk surgical patients from
the Cochrane Controlled Trial Register (2005, issue 1) and from
the EMBASE and MEDLINE databases (1966–30 April 2005),
without any language restriction, were included. Two reviewers
reviewed the quality of the studies and performed data
extraction independently.
Results Seven randomised controlled studies with a total of
814 immunocompetent high-risk surgical patients were
considered. The use of prophylactic fluconazole was associated
with a reduction in the proportion of patients with candidaemia
(relative risk [RR] = 0.21, 95% confidence interval [CI] = 0.06–
0.72, P = 0.01; I2 = 0%) and fungal infections other than lower
urinary tract infection (RR = 0.39, 95% CI = 0.24–0.65, P =
0.0003; I2 = 0%), but was associated with only a trend towards
a reduction in hospital mortality (RR = 0.82, 95% CI = 0.62–
1.08, P = 0.15; I2 = 7%). The proportion of patients requiring
systemic amphotericin B as a rescue therapy for systemic fungal
infection was lower after prophylactic use of fluconazole (RR =
0.35, 95% CI = 0.17–0.72, P = 0.004; I2 = 0%). The proportion
of patients colonised with or infected with fluconazole-resistant
fungi was not significantly different between the fluconazole
group and the placebo group (RR = 0.66, 95% CI = 0.22–1.96,
P = 0.46; I2 = 0%).
Conclusion The use of prophylactic fluconazole in
immunocompetent high-risk surgical patients is associated with
a reduced incidence of candidaemia but with only a trend
towards a reduction in hospital mortality.
Introduction
Fungi are an increasingly important cause of nosocomial infec-
tions in intensive care units (ICUs) [1,2]. Systemic fungal
infections are difficult to diagnose and are associated with
substantial morbidity, attributable mortality, prolonged hospital
stay, and healthcare costs [1-6]. Despite advances in medical
technology and the development of new antifungal drugs, the
crude and attributable mortality of candidaemia has remained
unchanged in the past 20 years [7]. Candida spp. remain the
commonest type of fungal infections in the ICUs and candi-
daemia accounts for 15% of all nosocomial bloodstream infec-
tions in the United States [1], with similar trends being
reported worldwide [8].
The use of prophylactic antifungal therapy in ICU is controver-
sial, although evidence from observational studies suggests
that antifungal prophylaxis is associated with a reduced risk of
candidaemia [9]. The risk factors associated with candidaemia
are prevalent in high-risk or critically ill surgical patients, and
these include the presence of a central venous catheter, acute
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renal failure, total parenteral nutrition, gastrointestinal perfora-
tion, and prior surgery [9,10]. Antifungal prophylaxis appears
more beneficial for non-neutropenic critically ill surgical
patients than for critically ill medical patients [10,11].
An antifungal agent selected for prophylaxis should have an
appropriate spectrum of activity, should be easily delivered,
and should have few adverse events [11]. Fluconazole
appears suitable and its efficacy has been evaluated in several
randomised controlled clinical trials involving high-risk surgical
patients, with variable results. In addition to its antifungal activ-
ity, fluconazole has been demonstrated to bind to neutrophil
surface receptors and to upregulate intracellular signalling
pathways, leading to enhanced oxygen free radical release
and chemotaxis in vitro [12]. It has been postulated that this
immunomodulation effect may explain, at least in part, the ben-
eficial effect of fluconazole on clinical outcome in patients with
gut perforation [13]. We conducted a meta-analysis to inves-
tigate the effects of prophylactic fluconazole on the incidence
of candidaemia and hospital mortality in immunocompetent
high-risk surgical patients.
Materials and methods
The literature search was performed on the Cochrane Control-
led Trials Register (2005, issue 1) and the EMBASE and
MEDLINE databases (1966–30 April 2005). Only randomised
control clinical trials involving immunocompetent critically ill or
high-risk surgical adult patients were included. For studies
involving a mixture of surgical and non-surgical patients, only
data from the surgical subgroup of patients were retrieved if
possible. Studies involving the use of fluconazole antifungal
prophylaxis for liver transplantation or for neutropenic cancer
patients were excluded because they included immunosup-
pressed patients.
During the electronic database search, the following exploded
MeSH terms were used: 'fluconazole' or 'antifungal' with 'criti-
cally ill', 'intensive care', 'trauma' or 'burns'. The reference lists
of related reviews and identified original articles were
searched for relevant trials. Finally, to ensure all suitable stud-
ies were included, the websites of the International Network of
Agencies of Health Technology Assessment and the Interna-
tional Society of Technology Assessment in Health Care were
searched and the company manufacturing fluconazole (Medi-
cal Department, Pfizer Australia Pty. Ltd., West Ryde NSW
Figure 1
Flow chart showing study inclusion and exclusion in this meta-analysis Flow chart showing study inclusion and exclusion in this meta-analysis.Available online http://ccforum.com/content/9/6/R710
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Table 1
Characteristics of the included studies
Study Design Participants Interventions Outcomes Allocation 
concealment
Garbino et al. [15] Double-blind 220 patients, mixture of 
surgical and medical 
critically ill adult patients; 
mean age = 54 years, mean 
APACHE II score = 19.4, 
mean ICU stay = 8.4 days, 
mean mortality = 39.5%
Intravenous fluconazole 100 
mg/day until a fungal 
infection developed, 
withdrawn from mechanical 
ventilation, or suspicion of a 
serious adverse event. 
Duration of study = 30 
months
Hospital mortality, proportion 
of patients with 
candidaemia, other fungal 
infections, adverse events 
requiring cessation of study 
drug, and patients required 
rescue therapy using 
systemic amphotericin B
Adequate
Pelz et al. [16] Double-blind 260 critically ill surgical adult 
patients; mean age = 64 
years, mean APACHE III 
score = 64, mean ICU stay 
= 5 days, mean mortality = 
11.5%
Loading dose of 800 mg 
enteral fluconazole followed 
by 400 mg daily (reduced to 
200 mg daily if creatinine 
clearance <25 ml/min) until 
3 days after ICU discharge, 
or death, or clinical decision 
to start systemic antifungal 
therapy. Duration of study = 
12 months
Hospital mortality, proportion 
of patients with 
candidaemia, and fungal 
infections, proportion of 
patients requiring rescue 
therapy using amphotericin 
B, proportion of patients 
colonised with or infected 
with fluconazole-resistant 
fungi, and the total length of 
hospital stay
Adequate
Eggimann et al. [17] Double-blind 43 surgical adult patients with 
recurrent gut perforation or 
anastomotic leakage; mean 
age = 63 years, mean 
APACHE II score = 13, 
mean hospital mortality = 
39.5%
400 mg intravenous 
fluconazole daily until 
complete resolution of the 
intra-abdominal disease, or 
development of a fungal 
infection requiring antifungal 
therapy, or adverse event 
related to the study drug. 
Duration of study = 30 
months
Hospital mortality, proportion 
of patients with candidaemia 
and other fungal infection, 
proportion of patients with 
adverse events leading to 
cessation of study drug, 
proportion of patients 
colonised with or infected 
with fluconazole-resistant 
fungi, and the total length of 
hospital stay
Adequate
Sandven et al. [18] Double-blind 109 high-risk surgical patients 
with a confirmed intra-
abdominal perforation; mean 
age = 64 years, mean 
hospital mortality = 11.3%
A single dose of intravenous 
fluconazole 400 mg 
intraoperatively. Duration of 
study 15 months
Hospital mortality, and 
proportion of patients with 
fungal infection
Adequate
He et al. [19] Unclear 45 adult patients with severe 
pancreatitis with at least one 
organ dysfunction or 
hyperglycaemia; mean age = 
50 years, mean hospital 
mortality = 20%
Intravenous fluconazole 100 
mg/day until no organ failure 
was observed. Duration of 
study = 60 months
Hospital mortality, proportion 
of patients with fungal 
infection, proportion of 
patients requiring rescue 
therapy using amphotericin 
B, and total length of 
hospital stay
Unclear
Jacobs et al. [13] Double-blind 34 patients with septic shock 
from intra-abdominal sepsis; 
mean age = 50 years, mean 
APACHE II score = 18, 
mean ICU stay = 20 days, 
mean hospital mortality = 
44%
Intravenous fluconazole 200 
mg/day until resolution of 
septic shock. Duration of 
study = 30 months
Hospital mortality, proportion 
of patients with 
candidaemia, other fungal 
infection, proportion of 
patients requiring rescue 
therapy using amphotericin 
B, and proportion of patients 
colonised with or infected 
with fluconazole-resistant 
fungi
Adequate
Ables et al. [20] Double-blind 119 trauma or after intra-
abdominal or intra-thoracic 
surgery adult patients with at 
least one of the following: 
central venous catheter, total 
parenteral nutrition, 
mechanical ventilation >24 
hours, or treatment with 
broad-spectrum antibiotics; 
mean age = 44 years, mean 
APACHE II score = 18, 
mean mortality = 19.3%
Either Intravenous, oral, or 
enteral fluconazole 800 mg 
loading following by 400 mg 
daily (doses adjusted with 
renal impairment); oral or 
enteral route was used when 
there was a presence of 
bowel sounds and no history 
of malabsorption. Duration of 
study = 26 months
Hospital mortality, proportion 
of patients with 
candidaemia, proportion of 
patients with adverse events 
leading to cessation of the 
study drug, proportion of 
patients colonised with or 
infected with fluconazole-
resistant fungi, and total 
length of hospital stay
Adequate
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2114, Australia) was contacted. If necessary, the authors of
the identified trials were contacted to obtain additional infor-
mation and unpublished data that were important in the analy-
sis. No studies published in languages other than English were
found in the literature search.
Two independent reviewers examined the titles and the
abstracts of all identified trials to confirm they fulfilled the inclu-
sion criteria. They examined and recorded the trial characteris-
tics and outcomes independently, using a predesigned data
abstraction form. This abstraction form was used to record
information regarding the quality of the trial such as allocation
concealment, the randomisation method, blinding of treat-
ment, and the inclusion and exclusion criteria. The grading of
allocation concealment was based on the Cochrane approach
(i.e. adequate or uncertain or clearly inadequate). Any disa-
greements between the two independent reviewers were
resolved by consensus. Any duplicated publications were
combined to represent one single trial. Data were checked
and entered into the Review Manager (version 4.2.6 for Win-
dows, 2003; The Cochrane Collaboration, Oxford, UK) data-
base for further analyses.
The hospital mortality and the proportion of patients with can-
didaemia were chosen as the main outcomes of this meta-
analysis because they are the most specific clinically relevant
outcomes of invasive fungal infections. There were no missing
data for these two main outcomes in the included studies. The
other outcomes assessed in this study included the proportion
of patients colonised with or infected with fluconazole-resist-
ant fungi, the proportion of patients requiring rescue therapy
by systemic amphotericin B treatment, the proportion of
patients with an adverse effect requiring cessation of the study
drug, the proportion of patients with fungal infections other
than urinary tract infection, and the total length of hospital stay.
Urinary fungal infection is difficult to distinguish from colonisa-
tion, and for this reason these infections were excluded from
further analyses in the present study. The definition of prophy-
laxis failure requiring amphotericin B treatment varied between
different studies, but the common definition involved clinical
deterioration with positive fungal culture from blood, deep tis-
sue, or sputum.
Statistical analyses
The differences in categorical outcomes between the treat-
ment group and the placebo group were reported as the rela-
tive risk (RR) with the 95% confidence interval (CI), using a
random effect model. The difference in the total length of hos-
pital stay between the fluconazole group and the placebo
group was reported as weight mean difference in days, using
a random effect model. The presence of heterogeneity
between trials was assessed by chi-square statistics and the
extent of inconsistency was assessed by I2 statistics [14].
Sensitivity analyses were conducted after excluding one study
with unclear allocation concealment and one study that
recruited some medical patients in the trial. The publication
bias was assessed by funnel plot using hospital mortality as an
endpoint.
Figure 2
Forest plot showing the effect of prophylactic fluconazole on hospital mortality Forest plot showing the effect of prophylactic fluconazole on hospital mortality. RR, relative risk; CI, confidence interval.
Figure 3
Forest plot showing the effect of prophylactic fluconazole on the proportion of patients with candidaemia Forest plot showing the effect of prophylactic fluconazole on the proportion of patients with candidaemia. RR, relative risk; CI, confidence interval.Available online http://ccforum.com/content/9/6/R710
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Results
We identified 16 potentially eligible studies, of which seven
studies [13,15-20] fulfilled the inclusion criteria and were sub-
ject to meta-analysis (Figure 1). Five studies used the intrave-
nous route [13,15,17-19], one study used the enteral route
[16], and one study used either the intravenous or enteral
route to administer the study drug depending on the function
of the gastrointestinal tract [20]. The doses of fluconazole
ranged from 100 to 800 mg/day. One study used a single
intraoperative dose of fluconazole [18], and the other six stud-
ies used a prolonged course of prophylaxis until recovery from
the surgical illness or until a new onset of symptoms or until a
positive culture of fungi with the clinical diagnosis of invasive
fungal infection. One study recruited patients with acute pan-
creatitis [19], one study recruited patients with septic shock
secondary to intra-abdominal sepsis [13], two studies
recruited patients with gut perforation [17,18], and three stud-
ies recruited general surgical and trauma patients [15,16,20].
The mean Acute Physiology and Chronic Health Evaluation II
and Acute Physiology and Chronic Health Evaluation III scores
ranged from 18 to 19 and from 63 to 65, respectively. Six
studies had adequate allocation concealment and were defi-
nitely double-blinded. The details of all included studies are
described in Table 1.
There was a good overall consistency in the results, without
significant heterogeneity. The use of prophylactic fluconazole
was associated with a reduction in the proportion of patients
with candidaemia (RR = 0.21, 95% CI = 0.06–0.72, P = 0.01;
I2 = 0%) and fungal infections other than lower urinary tract
infection (RR = 0.39, 95% CI = 0.24–0.65, P = 0.0003; I2 =
0%), but was associated with no significant difference in hos-
pital mortality (RR = 0.82, 95% CI = 0.62–1.08, P = 0.15; I2
= 7%) (Figures 2, 3, 4). The proportion of patients requiring
systemic amphotericin B as a rescue therapy for systemic fun-
gal infection was lower after prophylactic use of fluconazole
(RR = 0.35, 95% CI = 0.17–0.72, P = 0.004; I2 = 0%). The
proportion of patients colonised with or infected with flucona-
zole-resistant fungi (RR = 0.66, 95% CI = 0.22–1.96, P =
0.46; I2 = 0%) (Figure 5) and the proportion of patients with
adverse events leading to cessation of the study drug (RR =
0.75, 95% CI = 0.22–2.58, P = 0.65; I2 = 0%) were not dif-
ferent between the fluconazole group and the placebo group.
The total length of hospital stay was no different between the
fluconazole group and the placebo group (weight mean differ-
ence = -0.4 days, 95% CI = -10.35 to 9.54, P = 0.94; I2 =
52.4%).
Excluding one study with unclear allocation concealment [19]
and one study that recruited some medical patients [15] did
not affect the magnitude and significance of the results. None
of the studies included a formal cost-effectiveness analysis.
Five studies received financial grant or drug support from
Pfizer Pharmaceuticals, Inc. – of which three studies stated
Figure 4
Forest plot showing the effect of prophylactic fluconazole on the proportion of patients with fungal infections Forest plot showing the effect of prophylactic fluconazole on the proportion of patients with fungal infections. RR, relative risk; CI, confidence 
interval.
Figure 5
Forest plot showing the effect of fluconazole on proportion of patients colonised with fluconazole-resistant fungi Forest plot showing the effect of fluconazole on proportion of patients colonised with fluconazole-resistant fungi. RR, relative risk; CI, confidence 
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explicitly that the funding agency was not involved in the col-
lection and analyses of the data.
Discussion
Significance of our findings
This meta-analysis shows the benefits of fluconazole prophy-
laxis on most of the clinically relevant outcomes in critically ill
or high-risk surgical patients. Fluconazole prophylaxis is asso-
ciated with a much lower risk of candidaemia (RR = 0.2) and
other candidal infections (RR = 0.4), with less requirement for
systemic amphotericin B as a rescue therapy, and with a very
safe adverse event profile, and is not associated with a signif-
icant increase in fluconazole-resistant fungi. However, we
could only observe a trend towards a modest reduction in hos-
pital mortality.
The candidaemia rate of 4.5% in the placebo arm of this meta-
analysis is consistent with the estimated risk of candidaemia in
patients with at least one risk factor for candidaemia. The risk
factors include total parenteral nutrition, acute renal failure,
central venous catheter, broad-spectrum antibiotics, immuno-
suppression, and prior surgery [9]. The beneficial effect of flu-
conazole on the risk of candidaemia as demonstrated in this
meta-analysis is also consistent with the results of a cohort
study on critically ill surgical patients [9] and with the results
of fluconazole prophylaxis in immunosuppressed patients
[30,31]. If our results are valid, the beneficial effect of flucona-
zole on candidaemia will be stronger than the effect of prophy-
lactic topical non-absorbable antifungal agents such as
amphotericin B or nystatin in critically ill patients [32].
Although prophylactic fluconazole is effective in reducing can-
didaemia, our results did not demonstrate a statistical signifi-
cant reduction in hospital mortality. However, the candidaemia
rate in the placebo arm of this meta-analysis is 4.5% and the
expected absolute risk reduction in hospital mortality is about
2.25% if we assume that the attributable mortality of candidae-
mia is 50% [7]. If the 20% RR reduction in hospital mortality
as demonstrated in this meta-analysis is valid, a prospective
randomised controlled trial (or a meta-analysis) of more than
2,000 patients will be needed to demonstrate such a reduc-
tion in hospital mortality, assuming that the baseline hospital
mortality of the study population is 25%. The number of
patients considered in this meta-analysis was therefore too
small to evaluate a mortality difference. The expected smaller
treatment effect of prophylactic fluconazole on hospital mortal-
ity compared with candidaemia also suggests there are other
important factors in determining mortality in patients at high
risk of invasive fungal infections [33], and any potential bene-
ficial immunomodulation effect of fluconazole, as suggested
by some authors [12,13], is unlikely to be clinically significant
in addition to its antifungal activity.
A pharmacoeconomic or cost-effectiveness analysis was not
performed in the studies included in this meta-analysis. Based
on the baseline risk of candidaemia of 4.5% in the placebo arm
of this meta-analysis, the number of patients needed to treat is
about 25 to prevent one episode of candidaemia. The cost of
200 mg fluconazole is about US$35 per day in Australia and
Switzerland [17] and a 2-week prophylactic course of flucona-
zole will therefore cost US$490 per patient. The cost to pre-
vent one documented episode of candidaemia is estimated to
be US$12,250, which is equivalent to 40% of the economic
cost of an episode of candidaemia (US$30,000) [34]. Prophy-
lactic fluconazole may therefore be potentially cost-effective
and justified in some high-risk surgical patients if the candidae-
mia rate in the selected ICU is high despite optimising other
preventive measures such as vigorous hand hygiene, central
venous catheter care, and prudent antimicrobial use [7].
Emergence of resistant fungi with widespread use of a prophy-
lactic antifungal agent is a concern even if the drug is cost-
effective. Our results did not demonstrate an increase in the
risk of colonisation with or infection with fluconazole-resistant
Figure 6
Funnel plot showing the possibility of a small publication bias Funnel plot showing the possibility of a small publication bias. RR, relative risk.Available online http://ccforum.com/content/9/6/R710
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fungi within the time frame of the clinical trials (mean = 29
months, median = 30 months, range = 12–60 months).
Whether prophylactic fluconazole will select or induce emer-
gence of fluconazole-resistant fungi in the longer term is still
controversial and remains a major consideration before it can
be recommended [35-37].
Limitations of the study
Meta-analyses are prone to bias. The quality of trials can affect
the direction and magnitude of the treatment effect in meta-
analyses. After excluding one study with unclear allocation
concealment or double blinding, the direction and magnitude
of the results of this meta-analysis remained unchanged. A fun-
nel plot (Figure 6) showed that there was a possibility of a
small publication bias, with a lack of small studies showing no
effect on mortality with the use of prophylactic fluconazole.
Second, although the results of this meta-analysis were fairly
consistent across the included studies, there were significant
differences in the diagnoses of the patients and the study pro-
tocols, especially in the doses of fluconazole used. The opti-
mal dose and route of administration of fluconazole as a
prophylactic agent cannot be evaluated from these pooled
studies [32,38].
Conclusion
In immunocompetent high-risk surgical patients, the use of
prophylactic fluconazole is associated with a reduced inci-
dence of candidaemia but with only a trend towards reduction
in hospital mortality. A large randomised controlled trial would
be needed to assess the cost-effectiveness and the risk of
inducing fluconazole-resistant fungi before prophylactic fluco-
nazole can be recommended in immunocompetent high-risk
surgical patients.
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